Fig. 2: Local (panel A) and systemic (panel B) solicited adverse reactions within 7 days after vaccination (solicited safety population). | Nature Communications

Fig. 2: Local (panel A) and systemic (panel B) solicited adverse reactions within 7 days after vaccination (solicited safety population).

From: Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase

Fig. 2

Percentages of participants in the solicited safety population, which consisted of all participants in the safety population (all randomly assigned participants who received the investigational product) who contributed any solicited adverse reaction data: recombinant vaccine, n = 71; mRNA-1010 50 µg, n = 71, mRNA-1020 50 µg, n = 71; mRNA-1020 100 µg, n = 67; mRNA-1020 150 µg, n = 70; mRNA-1030 25 µg, n = 71; mRNA-1030 50 µg, n = 72; mRNA-1030 100 µg, n = 72. Adverse reactions were graded in intensity by the extent to which they affected the participant’s daily activities as mild (grade 1), moderate (grade 2), severe (grade 3), or life-threatening (grade 4). When there were multiple adverse reactions of a specific term within 7 days, the worst grade was selected. In this study, no participants had a grade 4 solicited adverse reaction.

Back to article page